PRTN3 and rheumatoid arthritis: Currently, changes in the levels and antigenic scope of RA autoantibodies, particularly ACPA, are the best available biomarkers with which to follow progression towards disease onset [7, 79–81], but these have proven difficult to recapitulate in murine models.